Nobuhiko Fukuda

ORCID

Publication Activity (10 Years)

Years Active: 2021-2023
Publications (10 Years): 4

Top Venues

Therapeutic advances in medical oncology

Thoracic cancer

This page only lists publications with an associated author ORCID identifier.

Publications

Hiromi Matsumoto, Kohei Somekawa, Nobuyuki Horita, Suguru Ueda, Megumi Kaneko, Ayami Kaneko, Nobuhiko Fukuda, Ami Izawa, Chisato Kamimaki, Katsushi Tanaka, Kota Murohashi, Hiroaki Fuji, Yoichi Tagami, Ayako Aoki, Keisuke Watanabe, Yu Hara, Nobuaki Kobayash, Takeshi Kaneko
Adverse events induced by durvalumab and tremelimumab combination regimens: a systematic review and meta-analysis. Therapeutic advances in medical oncology 15 (2023)
Kohei Somekawa, Nobuyuki Horita, Ayami Kaneko, Yoichi Tagami, Nobuhiko Fukuda, Hiromi Matsumoto, Ho Namkoong, Yu Fujiwara, Kaoru Minegishi, Takeshi Fukumoto, Keisuke Watanabe, Yu Hara, Nobuaki Kobayash, Takeshi Kaneko
Adverse events induced by nivolumab and ipilimumab combination regimens. Therapeutic advances in medical oncology 14 (2022)
Nobuhiko Fukuda, Nobuyuki Horita, Ho Namkoong, Ayami Kaneko, Kohei Somekawa, Yoichi Tagami, Keisuke Watanabe, Yu Hara, Nobuaki Kobayash, Takeshi Kaneko
Best regimens for treating chemo-naïve incurable squamous non-small cell lung cancer with a programmed death-ligand 1 tumor proportion score of 1%-49%: A network meta-analysis. Thoracic cancer (2021)
Hiromi Matsumoto, Nobuaki Kobayash, Kohei Somekawa, Nobuhiko Fukuda, Ayami Kaneko, Chisato Kamimaki, Sousuke Kubo, Katsushi Tanaka, Yoichi Tagami, Shuhei Teranishi, Keisuke Watanabe, Nobuyuki Horita, Yu Hara, Masaki Yamamoto, Makoto Kudo, Harumi Koizumi, Kenji Miura, Naoki Miyazawa, Takeshi Kaneko
Pembrolizumab monotherapy versus pembrolizumab plus chemotherapy in patients with non-small-cell lung cancer: A multicenter retrospective trial. Thoracic cancer (2021)

Nobuhiko Fukuda.css-eqlu8i{font-size:small;padding-left:4px;}

Publication Activity (10 Years)

Top Topics

Top Venues

Nobuhiko Fukuda